Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert McCord

Vascular Surgery Birmingham, AL Medical Doctor

NPI 1467434498 CMS profile 202008

817 Princeton Avenue Sw, Suite 306, Birmingham, AL 35211

Open in the dashboard

General payments

$2,450

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert McCord of Birmingham, AL is reported in the CMS Open Payments database as having received $2,450 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $530 15
2024 General $534 14
2023 General $306 8
2022 General $170 7
2021 General $104 2
2020 General $493 10
2019 General $313 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert McCord
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Robert McCord were reported at $530. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Robert McCord Vascular Surgery median Middle half National median
2019 $313 $796 $226–$2,363 $163
2020 $493 $348 $118–$1,110 $114
2021 $104 $471 $158–$1,421 $132
2022 $170 $725 $222–$2,183 $149
2023 $306 $836 $257–$2,440 $160
2024 $534 $909 $252–$2,619 $164
2025 $530 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $1,030 26 payments
  2. Endologix, Inc. $309 3 payments
  3. Silk Road Medical, Inc. $274 8 payments
  4. Penumbra, Inc. $221 4 payments
  5. Medtronic Vascular, Inc. $151 2 payments
  6. LeMaitre Vascular, Inc. $83 5 payments
  7. CryoLife, Inc. $69 2 payments
  8. Janssen Pharmaceuticals, Inc $56 4 payments
  9. ConvaTec Inc. $42 2 payments
  10. Kerecis Limited $41 2 payments
  11. Other $176 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,450 66 payments
Products named General payments · program years 2019–2025
  1. EXCLUDER Conformable AAA Endoprosthesis with Active Control $398 12 payments
  2. GORE VIABAHN VBX Balloon Expandable Endo $192 1 payment
  3. Alto Abdominal Stent Graft System $176 2 payments
  4. Penumbra System $175 2 payments
  5. Endurant $151 2 payments
  6. ENROUTE Transcarotid Neuroprotection System $143 4 payments
  7. ENROUTE Transcarotid Stent System $143 4 payments
  8. ENHANCE Transcarotid Peripheral Access Kit $143 4 payments
  9. ENROUTE 0.014 Guidewire $143 4 payments
  10. Conformable TAG Thoracic Endoprosthesis $140 1 payment
  11. Other $1,713 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

779

Median for Vascular Surgery: 122

Drug cost

$35,110

Median for Vascular Surgery: $14,135

Branded share of claims

29%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 553 $12,679
Xarelto Rivaroxaban Brand 22 $10,472
Eliquis Apixaban Brand 14 $10,301
Clopidogrel Clopidogrel Bisulfate Brand 58 $877
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 120 $730
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$86,220

Medicare's payments for the services billed

Medicare patients

636

Average age 75

Services billed

979

351 women, 285 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Chronic kidney disease 44%
Diabetes 43%
Ischemic heart disease 42%
COPD 34%
Heart failure 33%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record